Malcolm J. Moore
Division of Medical Oncology
Princess Margaret Hospital
Toronto
Canada
Name/email consistency: high
- Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Moore, M.J., Goldstein, D., Hamm, J., Figer, A., Hecht, J.R., Gallinger, S., Au, H.J., Murawa, P., Walde, D., Wolff, R.A., Campos, D., Lim, R., Ding, K., Clark, G., Voskoglou-Nomikos, T., Ptasynski, M., Parulekar, W. J. Clin. Oncol. (2007)
- Brief communication: a new combination in the treatment of advanced pancreatic cancer. Moore, M.J. Semin. Oncol. (2005)
- Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group. Townsley, C.A., Chi, K., Ernst, D.S., Belanger, K., Tannock, I., Bjarnason, G.A., Stewart, D., Goel, R., Ruether, J.D., Siu, L.L., Jolivet, J., McIntosh, L., Seymour, L., Moore, M.J. J. Clin. Oncol. (2003)
- Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Moore, M.J., Hamm, J., Dancey, J., Eisenberg, P.D., Dagenais, M., Fields, A., Hagan, K., Greenberg, B., Colwell, B., Zee, B., Tu, D., Ottaway, J., Humphrey, R., Seymour, L. J. Clin. Oncol. (2003)
- Pancreatic cancer: what the oncologist can offer for palliation. Moore, M.J. Can. J. Gastroenterol. (2002)